JP2011520877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520877A5 JP2011520877A5 JP2011509442A JP2011509442A JP2011520877A5 JP 2011520877 A5 JP2011520877 A5 JP 2011520877A5 JP 2011509442 A JP2011509442 A JP 2011509442A JP 2011509442 A JP2011509442 A JP 2011509442A JP 2011520877 A5 JP2011520877 A5 JP 2011520877A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- active ingredient
- cycloheptanecarbonyloxy
- azonia
- bicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004480 active ingredient Substances 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 8
- WZKCUYWQFWEJSC-AKFGGTECSA-O [(3r)-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound O([C@@H]1C2CC[N+](CC2)(C1)CC(=O)NC=1N=CC=CC=1)C(=O)C1(C=2C=CC=CC=2)CCCCCC1 WZKCUYWQFWEJSC-AKFGGTECSA-O 0.000 claims description 7
- -1 2-{[2- (4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl) ethyl] amino} Ethyl Chemical group 0.000 claims description 6
- UAGSBBULMRCCMT-TUXMBVIYSA-N [(3r)-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate;bromide Chemical group [Br-].O([C@@H]1C2CC[N+](CC2)(C1)CC(=O)NC=1N=CC=CC=1)C(=O)C1(C=2C=CC=CC=2)CCCCCC1 UAGSBBULMRCCMT-TUXMBVIYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 150000001450 anions Chemical class 0.000 claims description 6
- 229960004078 indacaterol Drugs 0.000 claims description 4
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims description 4
- ZVULMJYRVAVKCP-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-n-[2-[2-(4-hydroxy-2-oxo-3h-1,3-benzothiazol-7-yl)ethylamino]ethyl]-3-(2-naphthalen-1-ylethoxy)propanamide Chemical compound C1=CC=C2C(CCOCCC(=O)N(CCNCCC=3C=4SC(=O)NC=4C(O)=CC=3)CCN(CC)CC)=CC=CC2=C1 ZVULMJYRVAVKCP-UHFFFAOYSA-N 0.000 claims description 3
- GHQXRNRNBBBEQN-UHFFFAOYSA-N n-cyclohexyl-3-[2-(3-fluorophenyl)ethylamino]-n-[2-[2-(4-hydroxy-2-oxo-3h-1,3-benzothiazol-7-yl)ethylamino]ethyl]propanamide Chemical compound C1=2SC(=O)NC=2C(O)=CC=C1CCNCCN(C(=O)CCNCCC=1C=C(F)C=CC=1)C1CCCCC1 GHQXRNRNBBBEQN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 229940127557 pharmaceutical product Drugs 0.000 claims 9
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 7
- 239000000048 adrenergic agonist Substances 0.000 claims 7
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 239000003149 muscarinic antagonist Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- PWJNDVAKQLOWRZ-UHFFFAOYSA-N 1-hydroxynaphthalene-2-sulfonic acid Chemical class C1=CC=C2C(O)=C(S(O)(=O)=O)C=CC2=C1 PWJNDVAKQLOWRZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 2
- LFXZSGVZSSMCMB-UHFFFAOYSA-N 2,5-dichlorobenzenesulfonic acid Chemical class OS(=O)(=O)C1=CC(Cl)=CC=C1Cl LFXZSGVZSSMCMB-UHFFFAOYSA-N 0.000 claims 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- JKWGPZJKRRPSHL-JLMMNGPTSA-O [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-(3-fluorophenyl)cycloheptane-1-carboxylate Chemical compound FC1=CC=CC(C2(CCCCCC2)C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)=C1 JKWGPZJKRRPSHL-JLMMNGPTSA-O 0.000 claims 1
- VHTIGXNEAZTOFX-IYKJVDJMSA-O [(3r)-1-[2-[(2-methylpyridin-4-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound C1=NC(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(CCCCCC2)C=2C=CC=CC=2)=C1 VHTIGXNEAZTOFX-IYKJVDJMSA-O 0.000 claims 1
- DQCMINAFBHBOOI-FZCUKYEHSA-O [(3r)-1-[2-[(5-fluoropyridin-2-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound N1=CC(F)=CC=C1NC(=O)C[N+]1(C[C@@H]2OC(=O)C3(CCCCCC3)C=3C=CC=CC=3)CCC2CC1 DQCMINAFBHBOOI-FZCUKYEHSA-O 0.000 claims 1
- DSOSUTCGTSBHKJ-QJYFYXOJSA-O [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-(3-fluorophenyl)cycloheptane-1-carboxylate Chemical compound FC1=CC=CC(C2(CCCCCC2)C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC=3N=CC=NC=3)C2)=C1 DSOSUTCGTSBHKJ-QJYFYXOJSA-O 0.000 claims 1
- UDWRGWVYJNZRME-HBUOLCFLSA-O [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound O([C@@H]1C2CC[N+](CC2)(C1)CC(=O)NC=1N=CC=NC=1)C(=O)C1(C=2C=CC=CC=2)CCCCCC1 UDWRGWVYJNZRME-HBUOLCFLSA-O 0.000 claims 1
- NKWQBIXNTADYFR-HBUOLCFLSA-O [(3r)-1-[2-oxo-2-(pyridazin-3-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound O([C@@H]1C2CC[N+](CC2)(C1)CC(=O)NC=1N=NC=CC=1)C(=O)C1(C=2C=CC=CC=2)CCCCCC1 NKWQBIXNTADYFR-HBUOLCFLSA-O 0.000 claims 1
- ILQZJPKOIMGJOM-LMEDFRRQSA-O [(3r)-1-[2-oxo-2-(pyridin-3-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound O([C@@H]1C2CC[N+](CC2)(C1)CC(=O)NC=1C=NC=CC=1)C(=O)C1(C=2C=CC=CC=2)CCCCCC1 ILQZJPKOIMGJOM-LMEDFRRQSA-O 0.000 claims 1
- 150000003842 bromide salts Chemical group 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical group C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
- 229960002329 methacholine Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004044 bronchoconstricting agent Substances 0.000 description 2
- 230000003435 bronchoconstrictive effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- WORMGNDAXQYVAV-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-n-[2-[2-(4-hydroxy-2-oxo-3h-1,3-benzothiazol-7-yl)ethylamino]ethyl]-3-(2-naphthalen-1-ylethoxy)propanamide;dihydrobromide Chemical compound Br.Br.C1=CC=C2C(CCOCCC(=O)N(CCNCCC=3C=4SC(=O)NC=4C(O)=CC=3)CCN(CC)CC)=CC=CC2=C1 WORMGNDAXQYVAV-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000005062 tracheal ring Anatomy 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BDDIUTHMWNWMRJ-UHFFFAOYSA-N octane;hydrobromide Chemical compound Br.CCCCCCCC BDDIUTHMWNWMRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0808710A GB0808710D0 (en) | 2008-05-13 | 2008-05-13 | New combination 296 |
| GB0808710.8 | 2008-05-13 | ||
| GB0900563.8 | 2009-01-14 | ||
| GB0900563A GB0900563D0 (en) | 2009-01-14 | 2009-01-14 | New combination |
| PCT/SE2009/050525 WO2009139708A1 (en) | 2008-05-13 | 2009-05-12 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011520877A JP2011520877A (ja) | 2011-07-21 |
| JP2011520877A5 true JP2011520877A5 (enExample) | 2012-06-07 |
Family
ID=41318921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509442A Pending JP2011520877A (ja) | 2008-05-13 | 2009-05-12 | ムスカリン受容体アンタゴニストおよびβ２−アドレナリン受容体アゴニストを含む医薬品 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110190309A1 (enExample) |
| EP (1) | EP2315589A4 (enExample) |
| JP (1) | JP2011520877A (enExample) |
| KR (1) | KR20110010725A (enExample) |
| CN (2) | CN102908624A (enExample) |
| AU (1) | AU2009247021B2 (enExample) |
| BR (1) | BRPI0912657A2 (enExample) |
| CA (1) | CA2723909A1 (enExample) |
| MX (1) | MX2010012019A (enExample) |
| RU (1) | RU2010147881A (enExample) |
| WO (1) | WO2009139708A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| JP4837800B2 (ja) | 2008-05-13 | 2011-12-14 | アストラゼネカ・アクチエボラーグ | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| KR101845257B1 (ko) | 2011-02-07 | 2018-04-04 | 삼성전자주식회사 | 이미지 센서 |
| JP2011195593A (ja) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL62140C (enExample) * | 1942-12-16 | |||
| GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| GR1001529B (el) * | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| US6223485B1 (en) * | 1996-06-07 | 2001-05-01 | Herman Miller, Inc. | Wall panel system |
| KR20000029703A (ko) * | 1996-07-29 | 2000-05-25 | 존 헤덴스트룀 | 아릴시클로알칸카르복실산에스테르,그것의용도,제약학적조성물및제조방법 |
| US6613795B2 (en) * | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| WO2002096855A2 (en) * | 2001-04-03 | 2002-12-05 | Aryx Therapeutics | Anticholinergic compounds and methods of use |
| US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| WO2008059239A1 (en) * | 2006-11-14 | 2008-05-22 | Astrazeneca Ab | Novel compounds 514 |
| TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702456D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| GB0702457D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
| GB0704000D0 (en) * | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
| JP4837800B2 (ja) * | 2008-05-13 | 2011-12-14 | アストラゼネカ・アクチエボラーグ | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
| JP2011195593A (ja) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
-
2009
- 2009-05-12 CN CN2012104520326A patent/CN102908624A/zh active Pending
- 2009-05-12 RU RU2010147881/15A patent/RU2010147881A/ru not_active Application Discontinuation
- 2009-05-12 US US12/992,226 patent/US20110190309A1/en not_active Abandoned
- 2009-05-12 EP EP09746868.0A patent/EP2315589A4/en not_active Withdrawn
- 2009-05-12 KR KR1020107025392A patent/KR20110010725A/ko not_active Withdrawn
- 2009-05-12 CN CN200980127403XA patent/CN102088976B/zh not_active Expired - Fee Related
- 2009-05-12 WO PCT/SE2009/050525 patent/WO2009139708A1/en not_active Ceased
- 2009-05-12 CA CA2723909A patent/CA2723909A1/en not_active Abandoned
- 2009-05-12 JP JP2011509442A patent/JP2011520877A/ja active Pending
- 2009-05-12 MX MX2010012019A patent/MX2010012019A/es active IP Right Grant
- 2009-05-12 AU AU2009247021A patent/AU2009247021B2/en not_active Ceased
- 2009-05-12 BR BRPI0912657A patent/BRPI0912657A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI343809B (en) | A pharmaceutical composition for inhibiting coronavirus | |
| US9980927B2 (en) | Use of tapentadol for inhibiting and/or treating depression and anxiety | |
| KR20200016889A (ko) | 과다 졸림증을 치료하기 위한 방법 및 조성물 | |
| JP2018513107A5 (enExample) | ||
| JP2021073232A (ja) | 呼吸器疾患の治療 | |
| JP2013516488A (ja) | 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療 | |
| JP2011520877A5 (enExample) | ||
| CN115227825A (zh) | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 | |
| US20170080044A1 (en) | Sublingual delivery of glatiramer acetate | |
| JP2009242366A (ja) | 持続性解熱鎮痛消炎剤 | |
| JP2013536206A5 (enExample) | ||
| US11406649B2 (en) | Treatment of upper aerodigestive tract disorders and cough | |
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| RU2011105463A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА | |
| JP2021503448A5 (enExample) | ||
| RU2010147881A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА | |
| CA3177652A1 (en) | Methods of treating pulmonary fibrosis | |
| JP2007509946A5 (enExample) | ||
| JP2010523662A (ja) | 睡眠関連呼吸障害を処置するための方法及び組成物 | |
| EP3704123A1 (en) | Hydrophobic acid addition salts and pharmaceutical formulations thereof | |
| JP2009508965A (ja) | 正常な呼吸リズムを回復するための組み合わせｓ−ニトロソチオールをベースとする製薬学的製品 | |
| BR0308984A (pt) | Formulações em pó adequadas para inalação | |
| US11813254B2 (en) | Compositions and methods for reducing laminitis of an animal hoof | |
| JP2013501770A (ja) | ウイルス感染症の治療 | |
| JP5463019B2 (ja) | エピナスチン類とエフェドリン類とを含有する気道杯細胞過形成を抑制するための医薬組成物 |